Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II adjuvant nivolumab 480 mg after esophagectomy
jRCT1051220172Phase 2Recruiting
- Sponsor
- Miyata Research Institute
- Start
- Apr 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of nivolumab in esophageal cancer, sponsored by Miyata Research Institute. Primary endpoint: Nivolumab-related Grade ≥3 immune-related adverse event incidence. Started Apr 2022; status: recruiting.
02
Drugs
03
Conditions
esophageal cancer
Beyond the preview
Go deeper on jRCT1051220172.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT1051220172.